JS Kim, JY Lee, JW Yang, KH Lee, M Effenberger… - Theranostics, 2021 - ncbi.nlm.nih.gov
Abstract Severe coronavirus disease 2019 (COVID-19) is characterized by systemic hyper- inflammation, acute respiratory distress syndrome, and multiple organ failure. Cytokine …
Since December 2019, over 150 million individuals have been infected with SARS-CoV-2 globally. While most cases (> 95%) are asymptomatic or mild, a small proportion develop …
P Kory, GU Meduri, J Iglesias… - Journal of Intensive …, 2021 - journals.sagepub.com
Abstract In December 2019, COVID-19, a severe respiratory illness caused by the new coronavirus SARS-CoV-2 (COVID-19) emerged in Wuhan, China. The greatest impact that …
ПА Воробьев, АП Момот, АА Зайцев, ВА Елыкомов… - Терапия, 2020 - elibrary.ru
В работе приводится методология разработки научно-обоснованных рекомендаций по диагностике и терапии синдрома диссеминированного внутри со суд и сто го …
Background Many studies investigate the role of pharmacological treatments on disease course in Corona Virus Disease 2019 (COVID-19). Sex disparities in genetics …
S Emeksiz, B Çelikel Acar, AE Kibar… - … Journal of Clinical …, 2021 - Wiley Online Library
Objective Although the initial reports of COVID‐19 cases in children described that children were largely protected from severe manifestations, clusters of paediatric cases of severe …
JC Chang - Vascular Health and Risk Management, 2021 - Taylor & Francis
COVID-19 sepsis is characterized by acute respiratory distress syndrome (ARDS) as a consequence of pulmonary tropism of the virus and endothelial heterogeneity of the host …
M Beraud, S Al Hashami, M Lozano, A Bah… - … and Apheresis Science, 2022 - Elsevier
The risk of mortality in patients with coronavirus disease 2019 (COVID-19) is largely related to an excessive immune response, resulting in a hyperinflammatory and hypercoagulable …
Background and objectives Cytokine release syndrome in COVID‐19 is due to a pathological inflammatory response of raised cytokines. Removal of these cytokines by …